Iron bioavailability regulates Pseudomonas aeruginosa interspecies interactions through type VI secretion expression

Area of Science:

• Microbiology
• Pulmonology
• Infectious Diseases

Background:

• Cystic fibrosis (CF) patients experience chronic respiratory infections.
• Pseudomonas aeruginosa (P. aeruginosa) increasingly dominates CF lung microbiota with age, correlating with disease progression.
• Understanding P. aeruginosa dominance is crucial for developing effective CF therapies.

Purpose of the Study:

• To investigate the mechanisms behind P. aeruginosa's dominance in the CF respiratory tract.
• To identify factors influencing P. aeruginosa's competitive advantage.
• To explore potential therapeutic targets to mitigate P. aeruginosa overgrowth.

Main Methods:

• Analysis of bacterial competition in dynamic iron concentrations relevant to CF exacerbations.
• Investigating the role of the TseT toxic effector in P. aeruginosa competitiveness.
• Correlating iron levels and TseT expression with microbial diversity in CF patient samples.

Main Results:

• P. aeruginosa utilizes dynamic iron availability to enhance competitiveness through TseT effector expression.
• Iron chelation therapy with deferiprone effectively inhibits TseT expression and P. aeruginosa competition.
• Iron concentration and TseT expression are significantly linked to reduced microbial diversity in CF lungs.

Conclusions:

• Iron-mediated TseT expression is a key driver of P. aeruginosa dominance in CF airways.
• Targeting iron metabolism with chelators like deferiprone presents a viable therapeutic strategy.
• Modulating iron and TseT offers a pathway to restore microbial balance and improve CF lung health.